Gatza Laboratory - Select Publications

  1. Kanlikilicer P, Bayraktar R, Denizli M, Rashed M, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin G, Sood AK, and Lopez-Berestein G (2018). Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in Ovarian Cancer. EBioMedicine. Online 25-Nov-2018.   PDF

  2. Ren J, Karagoz K, Gatza ML, Sadimir E, Singer E, Foran D, Xin Q (2018). Recurrence analysis on prostate cancer patients with Gleason Score 7 using integrated histopathology whole-slide images and genomic data through deep neural networks. Journal of Medical Imaging. PDF

  3. Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, Demaria S, Wang E, Bedognetti D, Jones WD, Mehta GA, Gatza ML, Perou CM, Page DB, Triozzi P and Miller LB. (2018). Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. OncoImmunology. 7(10) e140854. PMCID: Pending PDF

  4. Perekatt, AO Pooja Shah P, Cheung S, Wu A, Gandi H, Kuma N, Fang Q, Jariwala N, Patel N, Cehn L, Joshi S, Ahou A, Taketo MM, Xing J, Gatza ML, White EP, Verzi MP. (2018). SMAD4 suppresses WNT-driven de-differentiation and oncogenesis in the differentiated gut epithelium. Cancer Research 78 (17), 4878-4890. PMCID: PMC6125228. PDF

  5. Serrao A, Jenkins LM, Chumanevich A, Horst B, Liang J, Gatza ML, Lee NY, Roninson I, Broude E, and Mythreye K (2018). Mediator kinase CDK8/CDK19 drives YAP1 dependent BMP4 induced EMT in cancer. Oncogene. 37(35):4792-4808. PMCID: Pending PDF

  6. Liu J, Zhang C,  Zhao Y, Yue X, Huang S, Chen J, Wu H, Tomsky K, Teutle M, Khella CA, Gatza ML, Xia D, Gao J; Haffty BG, Hu W, Feng Z. (2017). Parkin targets HIF-1α for ubiquitination and degradation to inhibit tumor progression. Nature Communications. Online 28 Nov 2017  PDF
  7. Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr DB, Karagoz K, Sciaky N, Gatza ML, Sharpless NE, Johnson GL, and Bear JE (2017). Intravital imaging of melanoma in combination with molecular analysis reveals key changes in stromal ECM and tumor reprogramming in response to MEKi. Cancer Research. Online 27 Nov 2017 PDF
  8. Lu K, Alcivar AL, Ma J, Foo TK, Zywea S, Huo Y, Kensler TW, Gatza ML and Xia B (2017). NRF2 induction supporting breast cancer cell survival is enabled by oxidative stress-induced DPP3-KEAP1 interaction. Cancer Research. Online April 17, 2017. PDF
  9. Mehta GA, Parker JS, Silva GO, Hoadley KA, Perou CM, Gatza ML. (2017). Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. Breast Cancer Research and Treatment. 162(3):439-450. PDF
  10. Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, Gatza ML, Wilkerson M, Perou CM, Yellapantula V, Huang KL, Lin C, McLellan MD, Yan P, Davies SR, Townsend RR, Skates SJ, Wang J, Zhang B, Kinsinger CR, Mesri M, Rodriguez H, Ding L, Paulovich AG, Fenyö D, Ellis MJ, Carr SA; NCI CPTAC. (2016). Proteogenomics connects somatic mutations to signaling in breast cancer. Nature. 534(7605):55-62. PDF
  11. Gatza ML and Carey LA (2016). Another breast cancer entity confirmed: Genomics of invasive lobular breast cancer. Journal of Clinical Oncology. 34(16):1838-9. PDF
  12. Ciriello G*, Gatza ML*, et al. (2015). Comprehensive molecular characterization of invasive lobular breast tumors. Cell. 163(2):506-19. *Authors contributed equally PDF
  13. Silva GO, He X, Parker JS, Gatza ML, et al.  (2015). Across Species DNA Copy Number Analyses Identifies Subtype-Specific Drivers of Breast Cancer Development. Breast Cancer Research and Treatment. 152(2):347-356. PDF
  14. Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, et al.  (2015). Activating PIK3CA mutations induce an EGFR/ERK paracrine signaling axis in basal-like breast cancer. Molecular and Cellular Proteomics. 14(7):1959-76. PDF
  15. Tian H, Liu J, Chen J, Gatza ML, Blobe GC (2015). Fibulin-3 is a Novel TGF-β pathway Inhibitor in the Breast Cancer Microenvironment. Oncogene. Online March 2015. PDF
  16. Gatza ML, et al. (2014). An integrated genomics approach identifies drivers of proliferation in luminal subtype human breast cancer. Nature Genetics. 46(10): 1051-1059. PDF
  17. Shats I, Gatza ML, et al. (2013). Cooperation between E2F1 and FOXO transcription factors provides a mechanism for control of E2F1-mediated transcription by survival signaling. Cancer Research.  73(19):6056-67. PDF
  18. Liu B, Shats I, Angus S, Gatza ML, Nevins JR (2013). Interaction of E2F7 with E2F1 and C-terminal binding protein (CtBP) provides a mechanism for E2F7-dependent transcription repression. Journal of Biological Chemistry. 288(34):245281-24589. PDF
  19. Mythreye K, Knelson EH, Gatza CE, Gatza ML, Blobe GC. (2013). TβRIII/β-arrestin2 suppresses epithelial derived cancer progression by regulating integrin α5β1 trafficking, function, and localization. Oncogene. 32 (11): 1416–1427. PDF
  20. Gatza ML, et al. (2011). Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Research13(3):R62. (Highly Accessed) PDF
  21. Chang JT, Gatza ML, et al. (2011). SIGNATURE: A workbench for gene expression signature analysis. BMC Bioinformatics. 12(1):443. (Highly Accessed). PDF
  22. Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, et al. (2011). The Type III TGF-β Receptor enhances colon cancer cell migration and anchorage independent growth. Neoplasia. 13(8): 758-770. PDF
  23. Shats I, Gatza ML, et al. (2011). Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Research. 71(5): 1772-1780. PDF

  24. Gatza ML, et al. (2010).  A pathway based classification of human breast cancer. Proc. Nat’l. Acad. Sci. 107(15):6994-6999. PDF
  25. Andrechek ER, Cardiff RD, Chang JT, Gatza ML, et al. (2009). Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc. Nat’l Acad. Sci. 106 (38):16387-16392. PDF
  26. Mori S, Chang JT, Andrecheck ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, et al. (2009).  Anchorage-independent cell growth signature identified tumors with metastatic potential. Oncogene. 28 (31): 2796-2805.  PDF
  27. Chang JT, Carvalho C, Mori S, Bild AH, Gatza ML, et al (2009).  A Genomic strategy to elucidate modules of oncogenic pathway signaling networks. Molecular Cell. 34(1): 104-114. PDF
  28. Gatza ML, et al. (2007). Ubiquitination of HTLV-I Tax mediates TSS complex disruption and Tax nuclear export in response to DNA damage. Retrovirology. 4: 95. PDF
  29. Gatza ML and Marriott SJ. (2006).Genotoxic stress and cellular stress alter the subcellular distribution of human T cell leukemia virus type 1 Tax through a CRM1 dependent mechanism.  Journal of Virology.  80 (13): 6657- 6668. PDF
  30. Gatza ML, et al. (2005). Impact of transforming viruses on cellular mutagenesis, genome stability, and cellular transformation. Environmental and Molecular Mutagenesis. 45 (2-3): 304-325. PDF
  31. Gatza ML, et al. (2003) Cellular Transformation by the HTLV-Tax protein, a jack-of-all-trades. Oncogene. 22 (33):5141-5149. PDF




image that says give now and support cancer research with link to giving page





Robert Wood Johnson Barnabas Health logo with link to Partners page





ScreenNJ logo with link to website






Big Ten Cancer Research Consortium





Rutgers Health